International biotechnology – Outperformance and income Under the leadership of its manager, Carl Harald Janson, International Biotechnology Trust (IBT) is building a track record of outperformance of both its benchmark, the Nasdaq Biotechnology Index and the average of its peer group (see page 13 of this note for the figures). The biotech sector, which IBT focuses on, […]
International Biotechnology beats benchmark on strong listed portfolio performance – In the year ended 31 August 2017, International Biotechnology Trust’s NAV rose from 575.1p to 672.9p, including a significant currency gain, equivalent to 14.4 pence per share. The NAV returned 20.9% in. Over the same period, the Shareholders total return was 30.5%. This compares to a rise […]
International Biotechnology Trust outperformed the Nasdaq Biotech Index over the year to the end of August 2016 as the fund’s NAV return was -1.7% against -3.8% for the index. Unfortunately, the discount widened from 5.7% to 13.5% and therefore the return to shareholders was -9.8%. Quoted portfolio The quoted portfolio outperformed the NBI by 1.1% in the […]
During the six months to 29 February 2016, International Biotechnology’s NAV fell by 17.7% from 585.1p to 481.7p. Over the same period, the share price fell by 22.9% from 551.5p to 425.0p. This compares with a decline in the NASDAQ Biotechnology Index (NBI) of 18.0% and a fall in the FTSE All-Share Index of 1.2%. The discount closed […]
International Biotechnology’s results for the six months ended 28 February 2015 are out and they show that the fund had a fantastic time with the net asset value rising by 44.5%. The share price was up 57.4% over this period as they bought back 23% of the company to cut the discount from 21.5% to […]
International Biotechnology Trust tries to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. International Biotechnology Trust invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or […]
International Biotech (IBT) announced its half-yearly report for the year ended 28 Feb 2023. The company’s share price was up 8.0% over the six month period, well ahead of the Nasdaq Biotechnology Index (NBI), which had a total return of 1.8%. The company’s Net Asset Value total return over the period was 6.1%. Over three […]
International Biotechnology Trust is in line for a big jump in its net asset value as its largest holding has been bid for. The trust owned 200,000 shares in Seagen Inc on 10 March, valued at $34.5m, making it the largest position in the trust, accounting for about 10.2% of the portfolio. On 13 March […]
International Biotech records modest rise in NAV in Jan SV Health-managed International Biotech Trust (IBT) reported a 1.4% rise in NAV and saw a 0.4% rise in its share price in January, according to its latest monthly update. The outcome was a little under the 2% rise in the sterling adjusted value of the NASDAQ […]
The Board of International Biotechnology Trust has announced two proposals which it believes will be of benefit to shareholders and potential investors. These include the introduction of dividend payments and amendments to International Biotechnology Trust’s investment policy to allow it to invest in unquoted funds. Both proposals will be subject to shareholder approval at a […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated